CLAIMS

1. Use of a compound selected from guanethidine, guanadrel, and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of heart failure with preserved ejection fraction (HFpEF).

2. Use of a compound selected from guanethidine, guanadrel, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for decreasing the risk of cardiovascular hospitalization in a patient diagnosed with heart failure with preserved ejection fraction (HFpEF).

3. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of heart failure with preserved ejection fraction (HFpEF), wherein the pharmaceutical composition comprises (a) a compound selected from guanethidine, guanadrel, and pharmaceutically acceptable salts thereof and (b) one or more second therapeutic agents selected from a diuretic, angiotensin converting enzyme (ACE) inhibitor, angiotensin receptor antagonist, mineralocorticoid antagonist (MRA), calcium channel blocker, beta-blocker, neprilysin inhibitor, angiotensin receptor-neprilysin inhibitor, angiotensin II receptor blocker, aldosterone antagonist, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, or any combination of any of the foregoing.

4. The use of claim 3, wherein the second therapeutic agent is selected from a beta-blocker, an ACE inhibitor, angiotensin receptor blocker, diuretic, aldosterone antagonist, SGLT-2 inhibitor, or any combination of any of the foregoing.

5. The use of any one of the preceding claims, wherein the patient has been diagnosed with HFpEF and has an LVEF greater than 45%.

6. The use of any one of the preceding claims, wherein the patient has been diagnosed with HFpEF and has an LVEF greater than 50%.

7. The use of any one of the preceding claims, wherein the patient has been diagnosed with HFpEF and exercise induced left atrial hypertension.

8. The use of any one of the preceding claims, wherein from about 0.5 to about 25 mg of guanethidine or a pharmaceutically acceptable salt thereof (based on guanethidine free base) daily is to be orally administered to the patient.

9. The use of any one of the preceding claims, wherein from about 0.5 to about 10 mg of guanethidine or a pharmaceutically acceptable salt thereof (based on guanethidine free base) daily is to be orally administered to the patient.

10. The use of any one of the preceding claims, wherein about 10 mg of guanethidine or a pharmaceutically acceptable salt thereof (based on guanethidine free base) is to be orally administered to the patient.

11. The use of any one of the preceding claims, wherein the compound is guanethidine free base.

12. The use of any one of claims 1-11, wherein the compound is guanethidine sulfate.

13. Use of a peripherally-acting antihypertensive agent that reduces excessive venoconstriction in a patient in the manufacture of a medicament for the treatment of heart failure with preserved ejection fraction (HFpEF).

14. The use of claim 13, wherein the peripherally-acting antihypertensive agent reduces the release of catecholamines, depletes peripheral catecholamine, decreases vascular resistance, or any combination of any of the foregoing.

15. A pharmaceutical composition comprising (a) guanethidine, guanadrel, or a pharmaceutically acceptable salt thereof and (b) one or more second therapeutic agents selected from a diuretic, angiotensin converting enzyme (ACE) inhibitor, angiotensin receptor antagonist, mineralocorticoid antagonist (MRA), calcium channel blocker, beta-blocker, neprilysin inhibitor, angiotensin receptor-neprilysin inhibitor, angiotensin II receptor blocker, aldosterone antagonist, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, and any combination of any of the foregoing.